Synimmune focuses on developing advanced cancer therapeutics through innovative technologies, particularly in the realm of antibody-drug conjugates (ADCs) and functional antibody screening. Their ADC technology aims to enhance the safety and efficacy of cancer treatments by delivering cytotoxic agents directly to cancer cells, thereby minimizing side effects for patients. This approach is designed to improve therapeutic outcomes and is supported by a robust pipeline that includes their lead program currently in clinical studies for acute myeloid leukemia (AML).

In addition to ADCs, Synimmune employs BiTAC technology, which is geared towards creating next-generation antibody formats. This technology is intended to further refine the targeting and delivery mechanisms of therapeutic antibodies, potentially leading to safer and more effective treatment options. The company emphasizes a commitment to pushing the boundaries of existing technologies, with a dedicated team focused on evolving their capabilities to develop better and safer medicines for cancer patients.

Germany

SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of cancer.

Synimmune

Company Details